Denosumab in postmenopausal women with low bone mineral density

New England Journal of Medicine

Volumn 354, Issue 8, 2006, Pages 821-831

  McClung, Michael R ^a,m   Michael Lewiecki, E ^b   Cohen, Stanley B ^c   Bolognese, Michael A ^d   Woodson, Grattan C ^e   Moffett, Alfred H ^f   Peacock, Munro ^g   Miller, Paul D ^h   Lederman, Samuel N ^c   Chesnut, Charles H ⁱ   Lain, Douglas ^j   Kivitz, Alan J ^k   Holloway, Donna L ^l   Zhang, Charlie ^l   Peterson, Mark C ^l   Bekker, Pirow J ^l  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^c RADIANT RESEARCH   (United States)

^d Bethesda Health Research   (United States)

^e Atlanta Research Center   (United States)

^f OB GYN Associates of Mid Florida   (United States)

^g INDIANA UNIVERSITY   (United States)

^h University of Colorado Health Sciences Center   (United States)

ⁱ UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^j Arthritis Associates and Osteoporosis Center of Colorado Springs   (United States)

^k Altoona Center for Clinical Research   (United States)

^l AMGEN INC   (United States)

^m OREGON OSTEOPOROSIS CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMG 162; TELOPEPTIDE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD ANALYSIS; BONE DENSITY; BONE TURNOVER; CARDIOTOXICITY; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; HIP; HUMAN; HYPERTENSION; INFECTION; INFLUENZA; INJURY; INTOXICATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEOPLASM; NEUROTOXICITY; NUTRITIONAL DISORDER; OSTEOLYSIS; PAIN; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RADIUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SINUSITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; URINARY TRACT INFECTION; VASCULAR DISEASE;

ALENDRONATE; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; CARRIER PROTEINS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 33344469853     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa044459     Document Type: Article

References (15)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
2. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87.
3. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004;2:CD004804.
4. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
5. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-38.
6. Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000;157:435-48.
7. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-602.
8. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-5.
9. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
10. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059-66.
11. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
12. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika 1965;52:591-611.
13. van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 1960;37:351-61.
14. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
15. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 2000;12:1-12.